Lv3
210 积分 2023-01-10 加入
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”
3天前
已完结
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer
3天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
8天前
已完结
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
9天前
已完结
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
12天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
26天前
已完结
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
26天前
已完结
The Breast: Aims and Scope
29天前
已完结
Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome
1个月前
已完结
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study
1个月前
已完结
皖公网安备34019202002308
